Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,121 questions · 2,186 findings · 242 reviews

No studies found 493 · 22.6%GRADE not reported 158 · 7.2%Very low 600 · 27.4%Low 474 · 21.7%Moderate 364 · 16.7%High 97 · 4.4%

Levofloxacin vs usual care

All‐cause mortality during hospital stay and all‐cause mortality at 1 year · people with endocarditis caused by Staphylococcus aureus

It is very uncertain whether levofloxacin changes all‐cause mortality during hospital stay and all‐cause mortality at… compared with standard treatment (very low certainty).

1 finding from 1 review

Glycopeptide (vancomycin or teicoplanin) plus aminoglycoside (gentamicin) vs beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin)

All‐cause mortality during hospital stay and all‐cause mortality at 1 year · people with endocarditis due to Staphylococcus aureus in drug abusers

The review found no eligible studies for this question.

1 finding from 1 review

Glycopeptide (vancomycin or teicoplanin) plus aminoglycoside (gentamicin) vs beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin)

Cure · people with endocarditis due to Staphylococcus aureus in drug abusers

Glycopeptide (vancomycin or teicoplanin) plus aminoglycoside… may leads to lower cure compared with beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin) (low certainty).

1 finding from 1 review

Glycopeptide (vancomycin or teicoplanin) plus aminoglycoside (gentamicin) vs beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin)

Adverse events · people with endocarditis due to Staphylococcus aureus in drug abusers

It is very uncertain whether glycopeptide (vancomycin or teicoplanin) plus aminoglycoside… changes adverse events compared with beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin) (very low certainty).

1 finding from 1 review

Glycopeptide (vancomycin or teicoplanin) plus aminoglycoside (gentamicin) vs beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin)

Need for cardiac surgical interventions · people with endocarditis due to Staphylococcus aureus in drug abusers

The review found no eligible studies for this question.

1 finding from 1 review

Beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) vs beta‐lactam (ceftriaxone)

All‐cause mortality during hospital stay and all‐cause mortality at 1 year · people with infective endocarditis due to penicillin‐susceptible Streptococci

The review found no eligible studies for this question.

1 finding from 1 review

Beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) vs beta‐lactam (ceftriaxone)

Cure · people with infective endocarditis due to penicillin‐susceptible Streptococci

Beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) showed no clear difference in cure compared with beta‐lactam (ceftriaxone) (low certainty).

1 finding from 1 review

Beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) vs beta‐lactam (ceftriaxone)

Adverse events · people with infective endocarditis due to penicillin‐susceptible Streptococci

It is very uncertain whether beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) changes adverse events compared with beta‐lactam (ceftriaxone) (very low certainty).

1 finding from 1 review

Beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) vs beta‐lactam (ceftriaxone)

Need for cardiac surgical interventions · people with infective endocarditis due to penicillin‐susceptible Streptococci

It is very uncertain whether beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) changes need for cardiac surgical interventions compared with beta‐lactam (ceftriaxone) (very low certainty).

1 finding from 1 review

Beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) vs beta‐lactam (ceftriaxone)

Uncontrolled infection · people with infective endocarditis due to penicillin‐susceptible Streptococci

It is very uncertain whether beta‐lactam (ceftriaxone) plus aminoglycoside (gentamicin) changes uncontrolled infection compared with beta‐lactam (ceftriaxone) (very low certainty).

1 finding from 1 review

Fosfomycin plus imipenem vs vancomycin

All‐cause mortality during hospital stay and all‐cause mortality at 1 year · people with infective endocarditis due to methicillin‐resistant Staphylococcus aureus

It is very uncertain whether fosfomycin plus imipenem changes all‐cause mortality during hospital stay and all‐cause mortality at… compared with vancomycin (very low certainty).

1 finding from 1 review